Oklahoma Attorney General files lawsuit against CVS Caremark
Leerink Partners maintained a Market Perform rating on CVS Health (NYSE:CVS) shares while increasing the price target from $51.00 to $55.00. The adjustment reflects the firm's expectation of an earnings recovery despite ongoing challenges within the Health Care Benefits (HCB) sector.
Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without many pharmacy options.
Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical lawsuits against the biggest insulin makers and against the pharmacy middlemen that decide whether to cover the drugmakers’ products.
Evercore ISI has updated its outlook on CVS Health (NYSE:CVS) shares, raising the price target from $60.00 to $65.00 while maintaining an Outperform rating. The adjustment comes in anticipation of future performance dynamics,
As PBM services have traditionally been dominated by large companies such as CVS Caremark, Express Scripts and OptumRx, health systems are starting to create alternatives. Here are four more things to know:
The lawsuit filed by Attorney General Gentner Drummond will be the first case heard in the newly established Pharmacy Benefit Management Administrative Courts.
The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
For many living in America, healthcare is both complicated and expensive. But Mark Cuban thinks there's another way. The billionaire entrepreneur is making waves with a surprisingly simple approach
Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.
Attorney General Gentner Drummond sued CVS Caremark Tuesday in an Oklahoma administrative court alleging that the company is under reimbursing pharmacies for prescription drugs.
Attorney General Gentner Drummond sued CVS Caremark Tuesday in an Oklahoma administrative court alleging that the company is under reimbursing pharmacies for prescription drugs.